Literature DB >> 29164300

177Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?

Kambiz Rahbar1, Hojjat Ahmadzadehfar2, Martin Boegemann3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29164300     DOI： 10.1007/s00259-017-3892-0

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  4 in total

1.  Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.

Authors:  Howard I Scher; Michael J Morris; Walter M Stadler; Celestia Higano; Ethan Basch; Karim Fizazi; Emmanuel S Antonarakis; Tomasz M Beer; Michael A Carducci; Kim N Chi; Paul G Corn; Johann S de Bono; Robert Dreicer; Daniel J George; Elisabeth I Heath; Maha Hussain; Wm Kevin Kelly; Glenn Liu; Christopher Logothetis; David Nanus; Mark N Stein; Dana E Rathkopf; Susan F Slovin; Charles J Ryan; Oliver Sartor; Eric J Small; Matthew Raymond Smith; Cora N Sternberg; Mary-Ellen Taplin; George Wilding; Peter S Nelson; Lawrence H Schwartz; Susan Halabi; Philip W Kantoff; Andrew J Armstrong
Journal:  J Clin Oncol       Date:  2016-02-22       Impact factor: 44.544

2.  Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1.

Authors:  Matthew Smith; Johann De Bono; Cora Sternberg; Sylvestre Le Moulec; Stéphane Oudard; Ugo De Giorgi; Michael Krainer; Andries Bergman; Wolfgang Hoelzer; Ronald De Wit; Martin Bögemann; Fred Saad; Giorgio Cruciani; Antoine Thiery-Vuillemin; Susan Feyerabend; Kurt Miller; Nadine Houédé; Syed Hussain; Elaine Lam; Jonathan Polikoff; Arnulf Stenzl; Paul Mainwaring; David Ramies; Colin Hessel; Aaron Weitzman; Karim Fizazi
Journal:  J Clin Oncol       Date:  2016-07-11       Impact factor: 44.544

3.  German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients.

Authors:  Kambiz Rahbar; Hojjat Ahmadzadehfar; Clemens Kratochwil; Uwe Haberkorn; Michael Schäfers; Markus Essler; Richard P Baum; Harshad R Kulkarni; Matthias Schmidt; Alexander Drzezga; Peter Bartenstein; Andreas Pfestroff; Markus Luster; Ulf Lützen; Marlies Marx; Vikas Prasad; Winfried Brenner; Alexander Heinzel; Felix M Mottaghy; Juri Ruf; Philipp Tobias Meyer; Martin Heuschkel; Maria Eveslage; Martin Bögemann; Wolfgang Peter Fendler; Bernd Joachim Krause
Journal:  J Nucl Med       Date:  2016-10-20       Impact factor: 10.057

4.  PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival.

Authors:  K Rahbar; M Boegemann; A Yordanova; M Eveslage; M Schäfers; M Essler; H Ahmadzadehfar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-10-12       Impact factor: 9.236
  4 in total
  4 in total

1.  Pre- and intratherapeutic predictors of overall survival in patients with advanced metastasized castration-resistant prostate cancer receiving Lu-177-PSMA-617 radioligand therapy.

Authors:  Robin Wrenger; Michael Jüptner; Marlies Marx; Yi Zhao; Maaz Zuhayra; Amke Caliebe; Daniar Osmonov; Ulf Lützen
Journal:  BMC Urol       Date:  2022-07-04       Impact factor: 2.090

Review 2.  Targeted α-therapy of prostate cancer using radiolabeled PSMA inhibitors: a game changer in nuclear medicine.

Authors:  Rubel Chakravarty; Cerise M Siamof; Ashutosh Dash; Weibo Cai
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-08-20

Review 3.  From the respective expert viewpoints of the ANM specialty editors.

Authors:  Masayuki Inubushi; Miho Shidahara; Yasuyuki Takahashi; Mikako Ogawa; Yasushi Kiyono
Journal:  Ann Nucl Med       Date:  2019-11-19       Impact factor: 2.668

Review 4.  Radiolabelled Peptides for Positron Emission Tomography and Endoradiotherapy in Oncology.

Authors:  Christine Rangger; Roland Haubner
Journal:  Pharmaceuticals (Basel)       Date:  2020-01-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.